The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
The company admits defeat with zelenectide.
But this comes in second-line breast cancer, a use the group isn’t pursuing.
Ascentage hopes to become a new force in BTK.
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
